Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
Yu Fujiwara, Shumei Kato, Mary Nesline, Jeffrey M. Conroy, Paul DePietro, Sarabjot Pabla, Razelle Kurzrock
Topics & Concepts
Indoleamine 2,3-dioxygenaseMedicinePembrolizumabBlockadeKynurenineImmune checkpointCancer researchImmunotherapyTumor microenvironmentIpilimumabImmunosuppressionPD-L1PharmacologyImmunologyImmune systemInternal medicineReceptorTryptophanBiologyBiochemistryAmino acidTryptophan and brain disordersCancer Immunotherapy and BiomarkersImmune cells in cancer